Heart failure drug proscillaridin A targets MYC overexpressing leukemia through global loss of lysine acetylation.

Background: Cardiac glycosides are approved for the treatment of heart failure as Na/K pump inhibitors. Their repurposing in oncology is currently investigated in preclinical and clinical studies. However, the identification of a specific cancer type defined by a molecular signature to design targeted clinical trials with cardiac glycosides remains to be characterized.